BMJ: Using SGLT2 inhibitors reduces the risk of severe renal function events in diabeticpatients

Researchers recently assessed the relationship between sodium-glucose co-transportprotein 2 (SGLT2) inhibitors and the risk of severe renal function eventsresearch was conducted in Sweden, Denmark and Norway, with 29,887 new users of SGLT2 inhibitors participating in 2013-18 (of which Dagre net edifron 66.1 per cent, Ngre net 32.6 per cent and Kagre net 1.3 per cent), while recruiting 29? 887 patients with dipeptidepeptidease-4 inhibitors had an average follow-up time of 1.7 yearsThe main results of the study were serious kidney events, including renal replacement therapy, kidney-caused death and hospitalization for kidney eventsThe average age ofpatients was 61.3 years, 11108 (19%) had cardiovascular disease and 1974 (3%) had chronic kidney diseaseThe use of SGLT2 inhibitors reduced the risk of severe kidney events compared to patients using dipeptide-4 inhibitors (2.6 events per 1,000 people per 1000 people vs 6.2 events per 1000 people per year; a risk ratio of 0.42), with an absolute difference of 3.6 events per 1000 people per yearIn the secondary analysis, compared with patients with dipeptidepeptidease-4 inhibitors, patients with SGLT2 inhibitors had a risk ratio of 0.32, a risk of kidney events in hospital ations was 0.41 (0.32-0.52), and kidney-related deaths were 0.77In the sensitivity analysis, the risk ratio was 0.41-0.55 after adjusting factors such as glycitin, glomerular filtration, blood pressure, body mass index, and smokingstudies have shown that the use of sodium-glucose co-transporter 2 inhibitors can reduce the risk of severe renal function events